Sign Up for a Free Account
  • Updated 03.16.2020
  • Released 11.12.2002
  • Expires For CME 03.16.2023

Clinical trials in multiple sclerosis


This article includes discussion of clinical trials in multiple sclerosis, immunomodulatory agents in MS: clinical trials and therapy, trials in relapsing-remitting multiple sclerosis, trials in secondary progressive multiple sclerosis, and trials in primary progressive multiple sclerosis. The foregoing terms may include synonyms, similar disorders, variations in usage, and abbreviations.


The author reviews current data on FDA-approved multiple sclerosis relapse treatment options, including several pivotal trials that involved the approval of ocrelizumab for the use in both relapsing-remitting and primary progressive multiple sclerosis, as well as the data on the use of the subcutaneous of the CD19-depleting therapy, ofatumumab.

Key points

• Currently, there are 14 FDA-approved disease-modifying therapies available for the treatment of relapsing-remitting multiple sclerosis.

• Ocrelizumab, an anti-CD20 monoclonal antibody, was approved for the treatment of both relapsing-remitting and primary progressive multiple sclerosis.

• Due to the toxic side effects associated with its use, novantrone is no longer used in the treatment of multiple sclerosis.

• Due to life-threatening side effects, daclizumab, previously marketed as Zinbryta, was withdrawn from the market in March 2018.

This is an article preview.
Start a Free Account
to access the full version.

  • Nearly 3,000 illustrations, including video clips of neurologic disorders.

  • Every article is reviewed by our esteemed Editorial Board for accuracy and currency.

  • Full spectrum of neurology in 1,200 comprehensive articles.

  • Listen to MedLink on the go with Audio versions of each article.

Questions or Comment?

MedLink®, LLC

3525 Del Mar Heights Rd, Ste 304
San Diego, CA 92130-2122

Toll Free (U.S. + Canada): 800-452-2400

US Number: +1-619-640-4660



ISSN: 2831-9125